S.K. Menbaev ¹

1. «Kazakh Institute of Oncology and Radiology» JSC, Almaty, the Republic of Kazakhstan

DOI: https://www.doi.org/10.52532/2663-4864-2022-4-66-10-17

УДК: 616-006-036.22:578.834.1

Year: 2022 issure: 66 number: 4 pages: 10-17

Download PDF:

ABSTRACT

Relevance: The new coronavirus infection, COVID-19, has been spreading rapidly around the world since 2019, affecting the healthcare systems of most countries. According to recent studies, malignant diseases increase the susceptibility to COVID-19 and are a risk factor for worse clinical outcomes in COVID-19 patients. COVID-19 also increases the risk of disease progression in patients with malignancies.
The study aimed to: study the prevalence of COVID-19 among cancer patients in Kazakhstan.
Methods: The analysis included open-access articles published since 2019 and indexed in PubMed, Cochrane, Google Scholar, and e-Library by keywords “cancer,” “malignant neoplasms,” “COVID-19”, “cancer patients,” “mortality risk.” The official statistics data, medical information systems of the Republic of Kazakhstan (Electronic Register of Cancer Patients, Electronic Register of Inpatient Patients), and official periodicals on cancer incidence and mortality for 2020-2021 and COVID-19 incidence and mortality for 2020-2022 in Kazakhstan were studied.
Results: In the Republic of Kazakhstan, in 2020-2021, the highest cancer incidence was registered in the North Kazakhstan (1.79-1.87%), Pavlodar (1.57-1.63%), Karaganda (1.54-1.53%) and Kostanay (1.53%) regions. The lowest rates were recorded in the Turkestan (0.42-0.41%), Kyzylorda (0.57-0.59%), and Mangistau (0.62%) regions, and the city of Shymkent (0.60%). The highest cancer mortality in Kazakhstan was registered in the Turkestan (11.1%), Kyzylorda (10.2%), and Zhambyl (10.02%) regions in 2020, and in they Atyrau (25.4%), Turkestan (10.68%), and West Kazakhstan (10.30%) regions in 2021.
The mortality from COVID-19 among patients registered for cancer in 2020 was the highest in the city of Astana (1.06%), the Kyzylorda (0.46%) and Turkestan (0.33%) regions, and in 2021 – in the cities of Shymkent (1.05%) and Astana (1,00%), the Atyrau (0.93%) and West Kazakhstan (0.94%) regions.
Conclusion: Thus, COVID-19 prevalence among cancer patients and their increased mortality during the pandemic, including the cases where the main cause of death was not an oncological process but the consequences of the viral infection, evidence the need to adjust the rules of statistical recording of cancer patients morbidity and mortality, the algorithms and protocols of diagnosis and treatment of cancer patients.
Keywords: cancer, malignant neoplasms (MN), COVID-19, cancer patients, mortality risk.

List of sources used:

1. Contini C., Di Nuzzo M., Barp N., Bonazza A., De Giorgio R., Tognon M., Rubino S. The novel zoonotic COVID-19 pandemic: An expected global health concern // J. Infect. Dev. Cries. – 2020. – Vol. 14(3). – P. 254-264. https://doi.org/10.3855/jidc.12671.
2. Tanu Singhal A. Review of Coronavirus Disease-2019 (COVID-19) // Indian J. Pediatr. – 2020. – Vol. 87(4). – P. 281-286. https://doi.org/10.1007/s12098-020-03263-6.
3. Chan K.W., Wong V.T., Wai Tang S.Ch. COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease // Am. J. Chin. Med. – 2020. – Vol. 48. – P. 737-762. https://doi.org/10.1142/S0192415X20500378.
4. Ge H., Wang X., Yuan X., Xiao G., Wang C., Deng T., Yuan Q., Xiao X. The epidemiology and clinical information about COVID-19 // Eur. J. Clin. Microbiol. Infect. Dis. – 2020. – Vol. 39. – P. 1011-1019. https://doi.org/10.1007/s10096-020-03874-z.
5. Harapan H., Itoh N., Yufika A., Winardi W., Keam S., Te H., Megawati D., Hayati Z., Wagner A.L., Mudatsir M. Coronavirus disease 2019 (COVID-19): A literature review // J. Infect. Public Health. – 2020. – Vol. 13(5). – P. 667-673. https://doi.org/10.1016/j.jiph.2020.03.019
6. Palacios Cruz M., Santos E., Velázquez Cervantes M.A., León Juárez M. COVID-19, a worldwide public health emergency // Rev. Clin. Esp. – 2020. – Vol. 221(1). – P. 55-61. https://doi.org/10.1016/j.rce.2020.03.001.
7. Velavan T.P., Meyer C.G. The COVID-19 epidemic // Trop. Med. Int. Health. – 2020. – Vol. 25(3). – P. 278-280. https://doi.org/10.1111/tmi.13383
8. Cao Y., Cai K., Xiong L. Coronavirus disease 2019: A new severe acute respiratory syndrome from Wuhan in China // Acta Virol. – 2020. – Vol. 64(2). – P. 245-250. https://doi.org/10.4149/av_2020_201
9. Tian S., Hu N., Lou J., Chen K., Kang X., Xiang Z., Chen H., Wang D., Liu N., Liu D., Chen G., Zhang Y., Li D., Li J., Lian H., Niu S., Zhang L., Zhang J. Characteristics of COVID-19 infection in Beijing // J. Infect. – 2020. – Vol. 80(4). – P. 401-406. https://doi.org/10.1016/j.jinf.2020.02.018
10. Pascarella G., Strumia A., Piliego C., Bruno F., Del Buono R., Costa F., Scarlata S., Agrò F.E. COVID-19 diagnosis and management: a comprehensive review // J. Intern. Med. – 2020. – Vol. 288(2). – P. 192-206. https://doi.org/10.1111/joim.13091.
11. Li L.Q., Huang T., Wang Y.Q., Wang Z.P., Liang Y., Huang T.B., Zhang H.Y., Sun W., Wang Y. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis // J. Med. Virol. – 2020. – Vol. 92(6). – P. 577-583. https://doi.org/10.1002/jmv.25757.
12. Jin Y., Yang H., Ji W., Wu W., Chen S., Zhang W., Duan G. Share. Virology, Epidemiology, Pathogenesis, and Control of COVID-19 // Viruses. – 2020. – Vol. 12(4). – P. 372. https://doi.org/10.3390/v12040372.
13. Lake M.A. What we know so far: COVID-19 current clinical knowledge and research // Clin. Med. (Lond). – 2020. – Vol. 20(2). – P. 124-127. https://doi.org/10.7861/clinmed.2019-coron
14. Yu J., Chai P., Ge Sh., Fan X. Recent understandings uoward Coronavirus disease 2019 (COVID-19) // Front. Cell. Dev. Biol. – 2020. – Vol. 8. – P. 476. https://doi.org/10.3389/fcell.2020.00476.
15. Esakandari H., Nabi-Afjadi M., Fakkari-Afjadi J., Farahmandian N., Miresmaeili S.M., Bahreini E. A comprehensive review of COVID-19 characteristics // Biol. Proced. Online. – 2020. – Vol. 22. – P. 19. https://doi.org/10.1186/s12575-020-00128-2.
16. Dhama K., Khan S., Tiwari R., Sircar S., Bhat S., Malik Y.S., Singh K.P., Chaicumpa W., Bonilla-Aldana D.K., Rodriguez-Morales A.J. Coronavirus Disease 2019-COVID-19 // Clin. Microbiol. Rev. – 2020. – Vol. 33(4). – Art. no. e00028-20. https://doi.org/10.1128/CMR.00028-20
17. Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C., Du B., Li L.J., Zeng G., Yuen K.Y., Chen R.C., Tang C.L., Wang T., Chen P.Y., Xiang J., Li S.Y., Wang J.L., Liang Z.J., Peng Y.X., Wei L., Liu Y., Hu Y.H., Peng P., Wang J.M., Liu J.Y., Chen Z., Li G., Zheng Z.J., Qiu S.Q., Luo J., Ye C.J., Zhu S.Y., Zhong N.S. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China // N. Engl. J. Med. – 2020. – Vol. 382(18). – P. 1708-1720. https://doi.org/10.1056/NEJMoa2002032.
18. Chan J.F., Yuan S., Kok K.H., To K.K., Chu H., Yang J., Xing F., Liu J., Yip C.C., Poon R.W., Tsoi H.W., Lo S.K., Chan K.H., Poon V.K., Chan W.M., Ip J.D., Cai J.P., Cheng V.C., Chen H., Hui C.K., Yuen K.Y. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster // Lancet. – 2020. – Vol. 395(10223). – P. 514-523. https://doi.org/10.1016/S0140-6736(20)30154-9
19. Bajema K.L., Oster A.M., McGovern O.L., Lindstrom S., Stenger M.R., Anderson T.C., Isenhour C., Clarke K.R., Evans M.E., Chu V.T., Biggs H.M., Kirking H.L., Gerber S.I., Hall A.J., Fry A.M., Oliver S.E. 2019-nCoV Persons Under Investigation Team; Persons Evaluated for 2019 Novel Coronavirus – United States, January 2020 // MMWR. – 2020. – Vol. 69(6). – P. 166-170. https://doi.org/10.15585/mmwr.mm6906e1
20. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China // Lancet. – 2020. – Vol. 395(10223). – P. 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
21. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., Xia J., Yu T., Zhang X., Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study // Lancet. – 2020. – Vol. 395(10223). – P. 507-513. https://doi.org/10.1016/S0140-6736(20)30211-7.
22. Meo S.A., Alhowikan A.M., Al-Khlaiwi T., Meo I.M., Halepoto D.M., Iqbal M., Usmani A.M., Hajjar W., Ahmed N. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV // Eur. Rev. Med. Pharmacol. Sci. – 2020. – Vol. 24. – P. 2012-2019. https://doi.org/10.26355/eurrev_202002_20379
23. Singh A., Shaikh A., Singh R., Singh A.K. COVID-19: From bench to bed side. // Diabetes Metab. Syndr. – 2020. – Vol. 14(4). – P. 277-281. https://doi.org/10.1016/j.dsx.2020.04.011.
24. Espinosa O.A., Zanetti A.D.S., Antunes E.F., Longhi F.G., Matos T.A., Battaglini P.F. Prevalence of comorbidities in patients and mortality cases affected by SARS-CoV2: a systematic review and meta-analysis // Rev. Inst. Med. Trop. Sao Paulo. – 2020 – Vol. 62. – Art. no. e43. https://doi.org/10.1590/S1678-9946202062043.
25. CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 – United States, February 12-March 28, 2020 // MMWR Morb. Mortal Wkly. Rep. – 2020. – Vol. 69(13). – P. 382-386. https://doi.org/10.15585/mmwr.mm6913e2
26. Liang W.H., Guan W.J., Li C.C., Li Y.M., Liang H.R., Zhao Y., Liu X.Q., Sang L., Chen R.C., Tang C.L., Wang T., Wang W., He Q.H., Chen Z.S., Wong S.S., Zanin M., Liu J., Xu X., Huang J., Li J.F., Ou L.M., Cheng B., Xiong S., Xie Z.H., Ni Z.Y., Hu Y., Liu L., Shan H., Lei C.L., Peng Y.X., Wei L., Liu Y., Hu Y.H., Peng P., Wang J.M., Liu J.Y., Chen Z., Li G., Zheng Z.J., Qiu S.Q., Luo J., Ye C.J., Zhu S.Y., Cheng L.L., Ye F., Li S.Y., Zheng J.P., Zhang N.F., Zhong N.S., He J.X. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China // Eur. Respir. J. – 2020. – Vol. 55(6). – Art. no. 2000562. https://doi.org/10.1183/13993003.00562-2020.
27. Wu Z., McGoogan J.M. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 cases from the Chinese Center for Disease Control and Prevention // JAMA. – 2020. – Vol. 323(13). – P. 1239-1242. https://doi.org/10.1001/jama.2020.2648.
28. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., Guan L., Wei Y., Li H., Wu X., Xu J., Tu S., Zhang Y., Chen H., Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study // Lancet. – 2020. – Vol. 395(10229). – P. 1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3.
29. Costa de Lucena T.M., da Silva Santos A.F., de Lima B.R., de Albuquerque Borborema M.E., de Azevêdo Silva J. Mechanism of inflammatory response in associated comorbidities in COVID-19 // Diabetes Metab. Syndr. – 2020. – Vol. 14(4). – P. 597-600. https://doi.org/10.1016/j.dsx.2020.05.025
30. Dayal D. We urgently need guidelines for managing COVID-19 in children with comorbidities // Acta Paediatr. – 2020. – Vol. 109(7). – P. 1497-1498. https://doi.org/10.1111/apa.15304.
31. Ejaz H., Alsrhani A., Zafar A., Javed H., Junaid K., Abdalla A.E., Abosalif K.O.A., Ahmed Z., Younas S. COVID-19 and comorbidities: Deleterious impact on infected patients // J. Infect. Public Health. – 2020. – Vol. 13(12). – P. 1833-1839. https://doi.org/10.1016/j.jiph.2020.07.014.
32. Chaimayo C., Kaewnaphan B., Tanlieng N., Athipanyasilp N., Sirijatuphat R., Chayakulkeeree M., Angkasekwinai N., Sutthent R., Puangpunngam N., Tharmviboonsri T., Pongraweewan O., Chuthapisith S., Sirivatanauksorn Y., Kantakamalakul W., Horthongkham N. Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand // Virol. J. – 2020. – Vol. 17(1). – Art. no. 177. https://doi.org/10.1186/s12985-020-01452-5.
33. Aghagoli G., Marin B.G., Soliman L.B., Sellke F.W. Cardiac involvement in COVID-19 patients: Risk factors, predictors, and complications: A review // J. Card. Surg. – 2020. – Vol. 35(6). – P. 1302-1305. https://doi.org/10.1111/jocs.14538.
34. Cheng Y., Luo R., Wang K., Zhang M., Wang Z., Dong L., Li J., Yao Y., Ge S., Xu G. Kidney disease is associated with in-hospital death of patients with COVID-19 // Kidney Int. – 2020. – Vol. 97(5). – P. 829-838. https://doi.org/10.1016/j.kint.2020.03.005.
35. Fidler M.M., Bray F., Soerjomataram I. The global cancer burden and human development: A review // Scand. J. Public Health. – 2018. – Vol. 46(1). – P. 27-36. https://doi.org/10.1177/1403494817715400.
36. Addeo A., Friedlaender A. Cancer and COVID-19: Unmasking their ties // Cancer Treat Rev. – 2020. – Vol. 88. – Art. no. 102041. https://doi.org/10.1016/j.ctrv.2020.102041.
37. Giannakoulis V.G., Papoutsi E., Siempos I.I. Effect of Cancer on Clinical Outcomes of Patients With COVID-19: A Meta-Analysis of Patient Data // JCO Glob. Oncol. – 2020. – Vol. 6. – P. 799-808. https://doi.org/10.1200/GO.20.00225.
38. Dai M., Liu D., Liu M., Zhou F., Li G., Chen Z., Zhang Z., You H., Wu M., Zheng Q., Xiong Y., Xiong H., Wang C., Chen C., Xiong F., Zhang Y., Peng Y., Ge S., Zhen B., Yu T., Wang L., Wang H., Liu Y., Chen Y., Mei J., Gao X., Li Z., Gan L., He C., Li Z., Shi Y., Qi Y., Yang J., Tenen D.G., Chai L., Mucci L.A., Santillana M., Cai H. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak // Cancer Discov. – 2020. – Vol. 10(6). – P. 783-791. https://doi.org/10.1158/2159-8290.CD-20-0422.
39. Aitken T., Chin K.L., Liew D., Ofori-Asenso R. Rethinking pandemic preparation: Global Health Security Index (GHSI) is predictive of COVID-19 burden, but in the opposite direction // J. Infect. – 2020. – Vol. 81(2). – P. 318-356. https://doi.org/10.1016/j.jinf.2020.05.001.
40. Desai A., Sachdeva S., Parekh T., Desai R. COVID-19 and Cancer: Lessons from a pooled meta-analysis // JCO Glob. Oncol. – 2020. – Vol. 6. – P. 557-559. https://doi.org/10.1200/GO.20.00097.
41. Cook G., Ashcroft A. J., Pratt G., Popat R., Ramasamy K., Kaiser M., Jenner M., Henshaw S., Hall R., Sive J., Stern S., Streetly M., Bygrave C., Soutar R., Rabin N., Jackson G.H. On behalf of the United Kingdom Myeloma Forum. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy // Br. J. Haematol. – 2020. – Vol. 190(2). – P. e83-e86. https://doi.org/10.1111/bjh.16874.
42. Sharpless N.E. COVID-19 and cancer // Science. – 2020. – Vol. 368(6497). – P. 1290. https://doi.org/10.1126/science.abd3377.
43. Aboueshia M., Hussein M.H., Attia A.S., Swinford A., Miller P., Omar M., Toraih E.A., Saba N., Safah H., Duchesne J., Kandil E. Cancer and COVID-19: analysis of patient outcomes // Future Oncol. – 2021. – Vol. 17(26). – P. 3499-3510. https://doi.org/10.2217/fon-2021-0121.
44. Хабар 24. В ВОЗ назвали COVID-19 угрозой для больных раком [Xabar 24. V VOZ nazvali COVID-19 ugrozoj dlya bol’nyx rakom (in Russ.)] https://24.kz/ru/news/in-the-world/item/525870-v-voz-nazvali-covid-19-ugrozoj-dlya-bolnykh-rakom. 04.02.2022.
45. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020 // CA Cancer J. Clin. – 2020. – Vol. 70(1). – P. 7-30. https://doi.org/10.3322/caac.21590.
46. Mohamadian M., Chiti H., Shoghli A., Biglari S., Parsamanesh N., Esmaeilzadeh A. COVID-19: Virology, biology and novel laboratory diagnosis // J. Gene. Med. – 2021. – Vol. 23(2). – P. e3303. https://doi.org/10.1002/jgm.3303
47. Liang W., Guan W., Chen R., Wang W., Li J., Xu K., Li C., Ai Q., Lu W., Liang H., Li S., He J. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China // Lancet Oncol. – 2020. – Vol. 21(3). – P. 335-337. https://doi.org/10.1016/S1470-2045(20)30096-6.
48. Sengupta R., Zaidi S.K. AACR Cancer Progress Report 2021: Discovery Science Driving Clinical Breakthroughs // Clin. Cancer Res. – 2021. – Vol. 27(21). – P. 5757-5759. https://doi.org/10.1158/1078-0432.CCR-21-3367.
49. Coronavirus-Monitor.info. Статистика развития пандемии коронавируса Covid-19 в Казахстане [Coronavirus-Monitor.info. Statistika razvitiya pandemii koronavirusa Covid-19 v Kazaxstane (in Russ.)]. https://coronavirus-monitor.info/country/kazakhstan/ 10.12.2022
50. Find How.org. Демографическая статистика Казахстана. Динамика численности населения за последние 12 месяцев в разрезе областей и городов Казахстана на основе статистических данных [Find How.org. Demograficheskaya statistika Kazaxstana. Dinamika chislennosti naseleniya za poslednie 12 mesyacev v razreze oblastej i gorodov Kazaxstana na osnove statisticheskix dannyx (in Russ.)]. https://findhow.org/2649-onlayn-schetchik-chislennosti-naseleniya-kazahstana.html 10.12.2022
51. Адылханов Т.А., Кайдарова Д.Р., Белихина Т.И., Рахманкулова А.М., Уағызханқызы Ж., Андреева О.Б. Клинические особенности коронавирусной инфекции среди пациентов с онкологическими заболеваниями в Республике Казахстан // Наука и Здравоохранение. – 2020. №5 (22). – С. 5-17 [Adylxanov T.A., Kajdarova D.R., Belixina T.I., Raxmankulova A.M., Uaғyzxanқyzy Zh., Andreeva O.B. Klinicheskie osobennosti koronavirusnoj infekcii sredi pacientov s onkologicheskimi zabolevaniyami v Respublike Kazaxstan // Nauka i Zdravooxranenie. – 2020. №5 (22). – S. 5-17 (in Russ.)]. https://doi.org/10.34689/SH.2020.22.5.001
52. Постановление Главного государственного санитарного врача. О дальнейшем проведении мер по предупреждению заболеваний коронавирусной инфекцией среди населения Республики Казахстан: утв. 11 июня 2021 года, № 28 [Postanovlenie Glavnogo gosudarstvennogo sanitarnogo vracha. O dal’nejshem provedenii mer po preduprezhdeniyu zabolevanij koronavirusnoj infekciej sredi naseleniya Respubliki Kazaxstan: utv. 11 iyunya 2021 goda, № 28 (in Russ.)]. https://adilet.zan.kz/rus/docs/D21RRA00028